Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 7

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 7
---
 conducting of clinical trials, manufacturing...  

  Risks relating to relying on third party suppliers for the active pharmaceutical ingredients in our drug candidate and drug products  

  Risks relating to our collaboration partners or our CROs ’ failure to comply with regulatory requirements pertaining to clinical trials  

Table of Contents

  Risks relating to our collaboration partners, principal investigators, CROs and other third-party contractors and consultants engaging in misconduct or other improper activities  

  Risks relating to relying on distributors for logistics and distributions services  

  Risks relating to the availability of benefits currently enjoyed by virtue of our association with CK Hutchison  

Other Risks and Risks Relating to Doing Business in China

  Risks relating to compliance with privacy and cybersecurity laws, information security policies and contractual obligations related to data privacy and security and any information technology o...  

  Risks relating to product liability claims or lawsuits  

  Risks relating to liabilities under anti-corruption laws, environmental, health and safety laws and laws relating to equity incentive plans  

  Risks relating to changes in laws, regulations and policies in China and uncertainties with respect to the PRC legal system, China ’ s currency exchange limits and PRC government tax incentives...  

Risks Relating to Intellectual Property

  Risks relating to our, our joint ventures and our collaboration partners ’ abilities to protect and enforce intellectual property rights and maintain confidentiality of trade secrets  

  Risks relating to infringing upon third parties ’ intellectual property rights  

Risks Relating to Our ADSs

  Risks relating to being delisted from the Nasdaq if the PCAOB is unable to inspect or investigate completely auditors located in China in the future  

  Risks relating to our largest shareholder which may limit the ability of other shareholders to influence corporate matters  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

You should carefully consider the following risk factors in addition to the other information set forth in this annual report. If any of the following risks were actually to occur, our company’ s business, financial condition and results of operations prospects could be adversely affected and the value of our ADSs would likely suffer.

Table of Contents

Risks Relating to Our Financial Position and Need for Capital

We may need substantial additional funding for our product development programs and commercialization efforts. If we are unable to raise capital on acceptable terms when needed, we could incur losses and be forced to delay, reduce or eliminate such efforts.

We expect to incur significant expenses in connection with